Press Releases

ODD Follows FDA Fast Track Designation Granted for ALLO-605 in Q2 2021 ALLO-605 is in Phase 1 in the IGNITE Trial and Part of Allogene’s Multi-Pronged Strategy Targeting BCMA BCMA Program Clinical Updates are Planned for Late 2022 SOUTH SAN FRANCISCO, Calif.

Interactive Experience Designed to Showcase the 136,000sf cGMP Facility Located in Newark, California Cell Forge 1 is Operational in Preparation for the Company’s First Pivotal Trial with ALLO-501A for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma Modular Facility Enables Flexibility

Data Continue to Highlight the Potential of ALLO-316 to Treat Both Solid Tumors and Hematologic Malignancies ALLO-316, in Phase 1 TRAVERSE Trial for the Treatment of Renal Cell Carcinoma, Granted Fast Track Designation (FTD) by the U.S. FDA in March 2022 SOUTH SAN FRANCISCO, Calif.

SOUTH SAN FRANCISCO, Calif. , April 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to participate in seven upcoming

Results Demonstrated Anti-BCMA CAR T Cells Derived from Healthy Donors Had Better Immune Fitness and Killing Activity Phase 1 AlloCAR T™ Trials Underway Evaluating ALLO-715 and ALLO-605 for the Treatment of Relapsed/Refractory Multiple Myeloma BCMA Program Clinical Update Expected by the End of

ALLO-316 is an allogeneic CAR T therapy candidate targeting CD70, which Has Broad Potential Application Across a Variety of Solid Tumors and Hematologic Malignancies Phase 1 TRAVERSE Trial of ALLO-316 for the Treatment of Renal Cell Carcinoma (RCC) ongoing SOUTH SAN FRANCISCO, Calif.

Comprehensive Report Highlights Efforts to Advance Diversity, Equity and Inclusion, Sustainable Business Practices, and Corporate Governance SOUTH SAN FRANCISCO, Calif. , March 01, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering

AlloCAR T™ Studies Resumed and Currently Enrolling Patients Following Removal of Clinical Hold in January 2022 Phase 1 Data from the ALPHA Trials in Relapsed/Refractory (RR) Non-Hodgkin Lymphoma Presented at ASH 2021 Demonstrated Potential for an AlloCAR T Product to be a Safe and Durable

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif. , Feb. 16, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today

SOUTH SAN FRANCISCO, Calif. , Jan. 26, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in four upcoming